<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494103</url>
  </required_header>
  <id_info>
    <org_study_id>H-28256-DOTTI</org_study_id>
    <secondary_id>DOTTI</secondary_id>
    <nct_id>NCT01494103</nct_id>
  </id_info>
  <brief_title>Administration of Donor T Cells With the Caspase-9 Suicide Gene</brief_title>
  <acronym>DOTTI</acronym>
  <official_title>Administration of Haploidentical Donor T Cells Transduced With the Inducible Caspase-9 Suicide Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be receiving a stem cell transplant as treatment for their disease. As part of&#xD;
      the stem cell transplant, patients will be given very strong doses of chemotherapy, which&#xD;
      will kill all their existing stem cells.&#xD;
&#xD;
      A close relative of the patient will be identified, whose stem cells are not a perfect match&#xD;
      for the patient's, but can be used. This type of transplant is called &quot;allogeneic&quot;, meaning&#xD;
      that the cells are from a donor. With this type of donor who is not a perfect match, there is&#xD;
      typically an increased risk of developing GvHD, and a longer delay in the recovery of the&#xD;
      immune system.&#xD;
&#xD;
      GvHD is a serious and sometimes fatal side-effect of stem cell transplant. GvHD occurs when&#xD;
      the new donor cells (graft) recognize that the body tissues of the patient (host) are&#xD;
      different from those of the donor.&#xD;
&#xD;
      In this study, investigators are trying to see whether they can make special T cells in the&#xD;
      laboratory that can be given to the patient to help their immune system recover faster. As a&#xD;
      safety measure, we want to &quot;program&quot; the T cells so that if, after they have been given to&#xD;
      the patient, they start to cause GvHD, we can destroy them (&quot;suicide gene&quot;).&#xD;
&#xD;
      Investigators will obtain T cells from a donor, culture them in the laboratory, and then&#xD;
      introduce the &quot;suicide gene&quot; which makes the cells sensitive to a specific drug called&#xD;
      AP1903. If the specially modified T cells begin to cause GvHD, the investigators can kill the&#xD;
      cells by administering AP1903 to the patient. We have had encouraging results in a previous&#xD;
      study regarding the effective elimination of T cells causing GvHD, while sparing a sufficient&#xD;
      number of T cells to fight infection and potentially cancer.&#xD;
&#xD;
      More specifically, T cells made to carry a gene called iCasp9 can be killed when they&#xD;
      encounter the drug AP1903. To get the iCasp9 gene into T cells, we insert it using a virus&#xD;
      called a retrovirus that has been made for this study. The AP1903 that will be used to&#xD;
      &quot;activate&quot; the iCasp9 is an experimental drug that has been tested in a study in normal&#xD;
      donors with no bad side-effects. We hope we can use this drug to kill the T cells.&#xD;
&#xD;
      The major purpose of this study is to find a safe and effective dose of &quot;iCasp9&quot; T cells that&#xD;
      can be given to patients who receive an allogeneic stem cell transplant. Another important&#xD;
      purpose of this study is to find out whether these special T cells can help the patient's&#xD;
      immune system recover faster after the transplant than they would have otherwise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If the patient is doing well after the stem cell transplant, and does not have severe GvHD,&#xD;
      s/he will be eligible to receive the special &quot;iCasp9&quot; T cells from Day 30 to 90 after&#xD;
      transplant. The specially selected and treated T cells will be given by vein (IV) once.&#xD;
&#xD;
      This is a dose escalation study. This means that at the beginning, patients will be started&#xD;
      on the lowest dose (1 of 5 different levels) of T cells. Once that dose schedule proves safe,&#xD;
      the next group of patients will be started at a higher dose. This process will continue until&#xD;
      all 5 dose levels are studied. If the side-effects are too severe, the dose will be lowered&#xD;
      or the T cell injections will be stopped.&#xD;
&#xD;
      If the patient develops GvHD after being given the specially treated T cells, we will&#xD;
      prescribe AP1903, which has been shown to kill cells carrying the iCasp9 gene. This drug will&#xD;
      be given as a 2-hour IV infusion.&#xD;
&#xD;
      We will continue to follow the patient weekly in the bone marrow transplant clinic for the&#xD;
      first month after the infusion, to check for side-effects of the treatment and for GvHD. The&#xD;
      patient will have the standard tests performed that all patients have after transplant, even&#xD;
      when not receiving special T cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">May 2029</completion_date>
  <primary_completion_date type="Anticipated">May 2029</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and immunological effects of AP1903 administration.</measure>
    <time_frame>14 days</time_frame>
    <description>To evaluate the clinical and immunological effects of AP1903 administration, a dimerizer drug used to activate an iCaspase9 suicide gene mechanism, to subjects who have received escalating doses of T lymphocytes expressing the iCaspase9 gene and developed acute graft-versus-host-disease (GvHD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cell dose that produces a greater than 25% risk of Grade II or greater GvHD.</measure>
    <time_frame>42 days</time_frame>
    <description>To discover the number of T cells/kg (up to 5 x 10^6/kg) that produce a greater than 25% risk of inducing Grade II or greater acute GvHD in these subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution and relative contribution of iCaspase9-modified T cells post-infusion.</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>To measure the subsequent immune reconstitution of recipients of iCaspase9 modified T cells (and dimerizer drug), and assess the relative contribution of endogenous T cell recovery and infused gene-modified T cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and disease-free survival.</measure>
    <time_frame>100 days and 1 year</time_frame>
    <description>To measure the overall and disease-free survival of recipients of iCaspase9 T cells at 100 days and at 1 year post-transplant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <condition>Familial Hemophagocytic Lymphohistiocytosis</condition>
  <condition>Hemophagocytic Syndrome</condition>
  <condition>Epstein Barr Virus Infection</condition>
  <condition>X-linked Lymphoproliferative Disease</condition>
  <arm_group>
    <arm_group_label>iCaspase9-transduced T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 5 dose levels are:&#xD;
1 x 10^4 T cells/kg&#xD;
1 x 10^5 T cells/kg&#xD;
5 x 10^5 T cells/kg&#xD;
1 x 10^6 T cells/kg&#xD;
5 x 10^6 T cells/kg&#xD;
AP1903 will be administered if there is development of Grade 1 or greater GvHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>iCaspase9-transduced T cells</intervention_name>
    <description>Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.</description>
    <arm_group_label>iCaspase9-transduced T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AP1903</intervention_name>
    <description>AP1903 will be administered if there is development of Grade 1 or greater GvHD.&#xD;
Dose: 0.4 mg/kg by IV over 2 hours.&#xD;
Up to 3 additional doses may be administered if the GvHD does not respond or gets worse.</description>
    <arm_group_label>iCaspase9-transduced T cells</arm_group_label>
    <other_name>AP1903 Dimerizer Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria at Time of Procurement:&#xD;
&#xD;
          1. Lack of a suitable conventional donor (i.e. 5/6 or 6/6 related, or 5/6 or 6/6&#xD;
             unrelated donor), or presence of a rapidly progressive disease not permitting time to&#xD;
             identify an unrelated donor.&#xD;
&#xD;
          2. High risk disease in one of the following:&#xD;
&#xD;
               -  Myelodysplastic syndrome (MDS) in one of the following categories: RCMD with an&#xD;
                  IPSS-R of intermediate, poor, or very poor, RAEB-1, or RAEB-2&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) after first relapse or primary refractory disease&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML) in Chronic Phase 2 or greater, Accelerated&#xD;
                  Phase or Blast Crisis&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL) after first relapse or primary refractory&#xD;
                  disease, or High-Grade Non Hodgkin lymphoma (NHL) Stage III or IV after first&#xD;
                  relapse or primary refractory disease&#xD;
&#xD;
               -  Hemophagocytic lymphohistiocytosis (HLH)&#xD;
&#xD;
               -  Familial hemophagocytic lymphohistiocytosis (FLH)&#xD;
&#xD;
               -  Viral-associated hemophagocytic syndrome (VAHS)&#xD;
&#xD;
               -  T or NK cell lymphoproliferative syndrome&#xD;
&#xD;
               -  X-linked lymphoproliferative disease (XLP)&#xD;
&#xD;
        Inclusion Criteria at Time of T Cell Infusion:&#xD;
&#xD;
          1. Engrafted with an absolute neutrophil count (ANC) &gt; 500 cells/ÂµL&#xD;
&#xD;
          2. Greater than or equal to 50% donor chimerism in either peripheral blood or bone&#xD;
             marrow, or relapse of their original disease&#xD;
&#xD;
          3. Life expectancy &gt; 30 days&#xD;
&#xD;
          4. Lansky/Karnofsky score greater than or equal to 60&#xD;
&#xD;
          5. Absence of severe renal disease (creatinine &gt; 2X upper limit of normal for age)&#xD;
&#xD;
          6. Absence of severe hepatic disease (direct bilirubin &gt; 3X upper limit of normal or SGOT&#xD;
             &gt; 3X upper limit of normal)&#xD;
&#xD;
          7. Oxygen saturation &gt; 94% on room air&#xD;
&#xD;
          8. Patient/Guardian able to give informed consent&#xD;
&#xD;
          9. AP1903 available in sufficient quantities to allow for treatment of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion Criteria at Time of T Cell Infusion:&#xD;
&#xD;
          1. GvHD&#xD;
&#xD;
          2. Severe intercurrent infection&#xD;
&#xD;
          3. Pregnancy*&#xD;
&#xD;
          4. Other investigational drugs in the prior 30 days&#xD;
&#xD;
               -  Pregnancy test only required for at-risk individuals, defined as female patients&#xD;
                  of childbearing potential who have received a reduced-intensity conditioning&#xD;
                  regimen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm K Brenner, MB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Malcolm Brenner</investigator_full_name>
    <investigator_title>Director/Professor, Center for Cell and Gene Therapy</investigator_title>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Chronic myelogenous leukemia</keyword>
  <keyword>Non Hodgkin lymphoma</keyword>
  <keyword>Hemophagocytic lymphohistiocytosis</keyword>
  <keyword>Familial hemophagocytic lymphohistiocytosis</keyword>
  <keyword>Hemophagocytic syndrome</keyword>
  <keyword>Epstein Barr virus infection</keyword>
  <keyword>X-linked lymphoproliferative disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

